GeneFrontier Corporation
Kashiwa, JP· latest recorded location
GeneFrontier Corporation is named on 12 US grants and 14 published applications in this corpus. Its most frequent classification is C07K (Peptides).
- Granted patents
- 12
- Published applications
- 14
- Inventors
- 16
- Granted in 2026 so far
- 1
- Most recent grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 3 |
| 2014 | 0 | 0 |
| 2015 | 2 | 1 |
| 2016 | 2 | 3 |
| 2017 | 2 | 0 |
| 2018 | 0 | 2 |
| 2019 | 2 | 2 |
| 2020 | 3 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 26 documents
Recent patents
- Cyclic peptide having CTLA-4 inhibitory activity and use thereof3 Mar 2026US 12,565,517 B2
- Anti-human CD69 antibody, and use thereof for medical purposes15 Dec 2020US 10,865,247 B2
- Human antibody against aggrecanase-type ADAMTS species for therapeutics of aggrecanase-related diseases5 May 2020US 10,640,573 B2
- Anti-ADAM28 antibody for treating cancer11 Feb 2020US 10,556,967 B2
- Anti-human membrane-type ADAM28 antibody25 Jun 2019US 10,329,358 B2
- Cyclic peptide having ctla-4 inhibitory activity and use thereof21 Mar 2024US 2024/0092836 A1
- Anti-human cd69 antibody, and use thereof for medical purposes25 Jun 2020US 2020/0199235 A1
- Anti-human cd69 antibody, and use thereof for medical purposes1 Aug 2019US 2019/0233521 A1
- Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases1 Aug 2019US 2019/0233541 A1
- Anti-adam28 antibody for treating cancer7 Jun 2018US 2018/0155448 A1
Most cited
By later US patents